mestastases
Conditions
Interventions
Experimental arm: single-fraction SBRT.AII lesions to be treated with radical radiotherapy will be treated with single-fraction SBRT. Acceptable ablative doses are developed in the protocol and range
Sponsors
European Organisation for Research in Treatment of Cancer (EORTC)
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: patient is part of the RP1822-OligoCare studyall active cancer lesions were or will be treated with radical intent (surgery or radiotherapy)all lesions that will be treated with radical radiotherapy have to be amenable to single-fraction SBRT
Exclusion criteria
Exclusion criteria: not fulfilling the inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In this clinical study, the primary objective is to demonstrate that single-fraction SBRT is not inferior to multiple-fraction SBRT in terms of grade 3+ SBRT-related toxicity within 12 months following treatment with radical radiotherapy in patients with oligometastatic disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objectives of this study are to compare patients treated with single-fraction SBRT with patients treated with the standard of care of multiple-fraction SBRT in terms of:Progression-free survival (PFS)Overall survival (OS)Local controlPattern of progression of oligometastases | — |
Countries
Austria, Belgium, Czech Republic, Italy, Netherlands, Slovenia, Spain, Switzerland, United Kingdom
Contacts
Public ContactP Braam
Radboud Universitair Medisch Centrum
Outcome results
None listed